Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289879 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Dita Gudra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Latvian Biomedical Research and Study Centre, Riga, Latvia. Hauptthemen laut MEDLINE: Helicobacter pylori, Klebsiella Infections. Die Arbeit nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund.
Abstract (Originalsprache)
The spread of extended-spectrum beta-lactamases (ESBLs) in nosocomial and community-acquired enterobacteria is an important challenge for clinicians due to the limited therapeutic options for infections that are caused by these organisms. Here, we developed a panel of ESBL coding genes, evaluated the abundance and prevalence of ESBL encoding genes in patients undergoing H . pylori eradication therapy, and summarized the effects of eradication therapy on functional profiles of the gut microbiome. To assess the repertoire of known beta lactamase (BL) genes, they were divided into clusters according to their evolutionary relation. Primers were designed for amplification of cluster marker regions, and the efficiency of this amplification panel was assessed in 120 fecal samples acquired from 60 patients undergoing H . pylori eradication therapy. In addition, fecal samples from an additional 30 patients were used to validate the detection efficiency of the developed ESBL panel. The presence for majority of targeted clusters was confirmed by NGS of amplification products. Metagenomic sequencing revealed that the abundance of ESBL genes within the pool of microorganisms was very low. The global relative abundances of the ESBL-coding gene clusters did not differ significantly among treatment states. However, at the level of each cluster, classical ESBL producers such as Klebsiella sp. for bla OXY ( p = 0.0076), Acinetobacter sp. for bla ADC ( p = 0.02297) and others, differed significantly with a tendency to decrease compared to the pre- and post-eradication states. Only 13 clusters were common across all three datasets, suggesting a patient-specific distribution profile of ESBL-coding genes. The number of AMR genes detected in the post-eradication state was higher than that in the pre-eradication state, which could be attributed, at least in part, to the therapy. This study demonstrated that the ESBL screening panel was effective in targeting ESBL-coding gene clusters from bacterial DNA and that minor differences exist in the abundance and prevalence of ESBL-coding gene levels before and after eradication therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Latvian Biomedical Research and Study Centre, Riga, Latvia.
- Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
- Faculty of Medicine, University of Latvia, Riga, Latvia.
ORCID-Profile: Dita Gudra, Girts Skenders, Kaspars Megnis
Förderung
- European Regional Development Fund
Zitieren
APA
Gudra, D., Silamikelis, I., Pjalkovskis, J., Danenberga, I., Pupola, D., Skenders, G., Ustinova, M., Megnis, K., Leja, M., Vangravs, R., & Fridmanis, D. (2023). Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori. PLOS ONE. https://doi.org/10.1371/journal.pone.0289879
Vancouver
Gudra D, Silamikelis I, Pjalkovskis J, Danenberga I, Pupola D, Skenders G, et al. Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori. PLOS ONE. 2023. doi:10.1371/journal.pone.0289879
BibTeX
@article{Gudra2023,
author = {Gudra, Dita and Silamikelis, Ivars and Pjalkovskis, Janis and Danenberga, Ilva and Pupola, Darta and Skenders, Girts and Ustinova, Maija and Megnis, Kaspars and Leja, Marcis and Vangravs, Reinis and Fridmanis, Davids},
title = {Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289879}
}
EUVIMED